NanJing Pharmaceutical Company Limited (SHA:600713)

SHA:600713 Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	1,692	4,563	2,372	2,328	2,095	1,482
Cash & Short-Term Investments	1,983	4,563	2,372	2,328	2,095	1,482
Cash Growth	71.05%	92.39%	1.87%	11.13%	41.32%	-29.52%
Accounts Receivable	20,285	15,098	16,209	19,304	15,251	14,262
Other Receivables	947.8	97.9	29.71	29.28	22.86	27.39
Receivables	21,232	15,196	16,238	19,334	15,274	14,289
Inventory	6,608	6,286	5,798	5,787	4,518	4,065
Other Current Assets	1,180	1,764	1,605	1,813	1,571	1,328
Total Current Assets	31,003	27,808	26,013	29,261	23,458	21,165
Property, Plant & Equipment	2,049	1,885	1,507	1,519	1,492	1,187
Long-Term Investments	277.91	283.47	237.64	206.45	254.18	324.12
Goodwill	72.17	72.17	72.17	72.17	72.17	74.17
Other Intangible Assets	204.56	215.68	218.98	245.28	268.11	282.17
Long-Term Deferred Tax Assets	264.87	243.43	222.82	224.93	180.78	185.92
Long-Term Deferred Charges	85.19	63.07	43.34	36.89	34.24	52.76
Other Long-Term Assets	87.97	102.74	95.58	84.69	126.24	138.93
Total Assets	34,045	30,674	28,410	31,651	25,886	23,410
Accounts Payable	10,135	10,176	9,694	10,131	8,064	7,634
Accrued Expenses	133.75	369.49	363.63	438.32	379.33	315.11
Short-Term Debt	3,996	3,760	4,574	8,414	7,036	7,642
Current Portion of Long-Term Debt	287.28	900.98	2,223	1,409	-	-
Current Portion of Leases	-	79.63	76.04	71.68	78.28	1.04
Current Income Taxes Payable	179	87.6	91.48	102.89	136.01	108.7
Current Unearned Revenue	268.64	278.67	103.57	219.12	74.78	75.24
Other Current Liabilities	6,446	1,441	1,441	1,498	1,756	1,427
Total Current Liabilities	21,446	17,094	18,566	22,284	17,525	17,203
Long-Term Debt	4,121	5,339	2,118	2,222	2,628	1,027
Long-Term Leases	190.86	116.18	119.02	103.23	124.4	2.51
Long-Term Unearned Revenue	266.96	277.62	297.06	293.17	304.61	265.33
Long-Term Deferred Tax Liabilities	62.69	59.05	55.41	54.24	69.9	92.1
Total Liabilities	26,087	22,886	21,155	24,956	20,652	18,589
Common Stock	1,309	1,309	1,310	1,310	1,042	1,042
Additional Paid-In Capital	2,454	2,466	2,460	2,429	1,380	1,652
Retained Earnings	3,152	2,973	2,611	2,217	1,778	1,388
Treasury Stock	-48.34	-20.9	-35.9	-38.58	-	-
Comprehensive Income & Other	106.96	111.24	89.72	81.98	406.6	176.6
Total Common Equity	6,974	6,838	6,435	6,000	4,606	4,258
Minority Interest	984.06	949.87	819.73	695.03	627.46	562.59
Shareholders' Equity	7,958	7,788	7,255	6,695	5,234	4,820
Total Liabilities & Equity	34,045	30,674	28,410	31,651	25,886	23,410
Total Debt	8,595	10,196	9,110	12,219	9,867	8,673
Net Cash (Debt)	-6,613	-5,634	-6,738	-9,891	-7,772	-7,190
Net Cash Per Share	-4.71	-4.32	-5.19	-7.89	-7.46	-6.90
Filing Date Shares Outstanding	1,266	1,309	1,310	1,310	1,042	1,042
Total Common Shares Outstanding	1,266	1,309	1,310	1,310	1,042	1,042
Working Capital	9,558	10,714	7,447	6,978	5,933	3,962
Book Value Per Share	5.51	5.22	4.91	4.58	4.42	4.09
Tangible Book Value	6,697	6,550	6,144	5,682	4,266	3,901
Tangible Book Value Per Share	5.29	5.00	4.69	4.34	4.10	3.75
Buildings	-	1,463	1,133	1,166	1,046	-
Machinery	-	928.24	890.32	839.29	762.13	-
Construction In Progress	-	237.27	130.08	80.23	153.4	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.